Moderna ( NASDAQ:MRNA – Get Free Report ) had its price objective cut by equities researchers at Royal Bank of Canada from $200.00 to $190.00 in a report released on Friday, Benzinga reports. The brokerage presently has an 'outperform' rating on the stock. Royal Bank of Canada's price objective would suggest a potential upside of 71.39% from the stock's current price. Other equities analysts have also recently issued reports about the company. Deutsche Bank Aktiengesellschaft cut Moderna from a 'buy' rating to a 'hold' rating and reduced their target price for the company from $200.

https://www.dailypolitical.com/2023/08/04/moderna-nasdaqmrna-price-target-cut-to-190-00-by-analysts-at-royal-bank-of-canada.html

#dailypolitical